The role of anti-Mullerian hormone and other correlates in patients with polycystic ovary syndrome
Authors:
Open Access
- 13 August 2023
- journal article
- research article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 39 (1) , 2247098
Abstract
Anti-Müllerian hormone (AMH) has recently emerged as a promising biomarker for the detection of polycystic ovarian morphology. In polycystic ovary syndrome (PCOS), an elevated level of AMH has been suggested to add value to the Rotterdam criteria in cases of diagnostic uncertainty. In this study, we evaluated the correlation between AMH and PCOS, and the potential role of AMH in PCOS diagnosis. A case-control study was performed on a total of 200 females, 100 of which were diagnosed with PCOS as per Rotterdam revised criteria (2003) and 100 as the control (non-PCOS group). Patient medical records were therefore retrieved for clinical, biochemical and ultrasound markers for PCOS diagnosis. Sensitivity, specificity, area under receiver operating characteristic (AUROC) curve, and multivariate linear regression models were applied to analyze our data. Mean serum levels of LH and AMH, and LH/FSH ratio were significantly different between compared groups. In the PCOS group, the mean serum AMH level was 6.78 ng/mL and LH/FSH ratio was 1.53 while those of controls were 2.73 ng/mL and 0.53, respectively (p < .001). The most suitable compromise between 81% specificity and 79% sensitivity was obtained with a cutoff value of 3.75 ng/mL (26.78 pmol/L) serum AMH concentration for PCOS prediction, with an AUROC curve of 0.9691. Serum AMH cutoff level of 3.75 ng/mL was identified as a convenient gauge for the prediction of PCOS and an adjuvant to the Rotterdam criteria.Keywords
All Related Versions
This publication has 59 references indexed in Scilit:
- Anti Mullerian Hormone: A Potential Marker for Recruited Non Growing Follicle of Ovarian Pool in Women with Polycystic Ovarian SyndromeJournal of Clinical and Diagnostic Research, 2013
- Role of vitamin D treatment in glucose metabolism in polycystic ovary syndromeFertility and Sterility, 2009
- Metabolic features of the reproductive phenotypes of polycystic ovary syndromeHuman Reproduction Update, 2009
- Obesity and Polycystic Ovary SyndromeObesity Management, 2007
- Polycystic ovary syndrome and hyperprolactinemia are distinct entitiesGynecological Endocrinology, 2007
- Low Serum 25-Hydroxyvitamin D Concentrations are Associated with Insulin Resistance and Obesity in Women with Polycystic Ovary SyndromeExperimental and Clinical Endocrinology & Diabetes, 2006
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndromeFertility and Sterility, 2004
- Müllerian Inhibitory Substance Induces Growth of Rat Preantral Ovarian Follicles1Biology of Reproduction, 2001
- Mechanism of Androgen Action in Cultured Dermal Papilla Cells Derived from Human Hair Follicles with Varying Responses to Androgens In VivoJournal of Investigative Dermatology, 1992
- Hirsutism in Polycystic Ovary SyndromeClinical Obstetrics and Gynecology, 1991